Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mitomics today announced that it has signed a non-exclusive agreement with LabMD to market its Prostate Core Mitomic Test in the US.

The PCM test is based on mitochondrial DNA and identifies a biomarker that indicates the presence of cancerous cells in prostate biopsy tissue. Thunder Bay, Ontario-based Mitomics said the test has a sensitivity of 84 percent with a negative predictive value of 91 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.